BERND SEIZINGER, MD PHD
CHAIRMAN OF THE BOARD
Dr Seizinger has held a number of senior executive and board positions in both US and European biotech and pharmaceutical companies (public and private) including President & CEO of GPC Biotech (Germany/US) in addition to Vice President positions at Bristol-Myers-Squibb, CSO of Genome Therapeutics, CEO/Chairman of CryptoMedix, Chairman of Aprea and Opsona Therapeutics. Prior to his corporate appointments, Dr Seizinger held senior faculty positions at Harvard Medical School and Massachusetts General Hospital and was a Visiting Professor at Princeton University during his tenure at Bristol-Myers Squibb.
CHRISTIAN ROHLFF, PHD
CHIEF EXECUTIVE OFFICER
Dr Rohlff has been CEO of Oxford BioTherapeutics since founding the company and acquiring key technology, bioinformatics data and intellectual property. He brings more than 20 years of experience in the international biotechnology industry. Following his PhD in Pharmacology from Georgetown University, Christian worked at the US National Cancer Institute in Bethesda, Maryland. Prior to founding OBT, he held a number of positions of increasing seniority with Oxford Glycosciences, and led the company’s partnerships in oncology with Pfizer, GSK, Bayer, Wyeth, Takeda, Oxford University and the FDA.
JEAN-PIERRE BIZZARI, MD
Dr Bizzari started his career as Head of the Oncology at the Institut de Recherches Internationales SERVIER. He has held a number of senior executive positions within the pharmaceutical industry, including a number of VP Clinical Oncology roles at Rhone-Poulenc Rorer, Aventis, Sanofi and Celgene. Dr Bizzari has been involved in the development of numerous compounds including anti-angiogenics (VEGF-trap), gene therapy, vaccines and bio-reductive agents. He was instrumental in the clinical development of several anticancer agents including Taxotere, Revlimid, and Vidaza. Dr Bizzari is a member of the Scientific Advisory Board of the French National Cancer Institute (INCA), and a board member of the European Organization of Research and Treatment of Cancer (EORTC). He holds a medical degree from the University of Nice (France) and trained as an oncologist at the Pitie Salpetriere hospital in Paris, the Ontario Cancer Institute in Toronto and the Mac Gill Cancer Centre in Montreal.
Mr. Gould is co-founder and director of Percipient Capital, a leading venture capital business supporting high growth companies. He is an experienced investor having worked in venture capital and private equity for over 20 years, personally leading investments into more than 40 companies, encompassing sectors as diverse as biotechnology, software, manufacturing, distribution and business services. He is also an experienced non-executive director and chairman, having served on the boards of several successful portfolio companies. Jason provided the original seed investment into OBT and has led subsequent investment rounds as the company has evolved and matured into a fully-fledged clinical stage oncology company. Jason has a BSc degree with first-class honors from the University of Manchester.